###### Summary box

What is already known about this topic?
=======================================

1.  Newer direct-acting agents including simeprevir (SMV) and sofosbuvir (SOF) have demonstrated greater efficacy and better tolerability in patients with hepatitis C.

2.  In randomised controlled trials (RCTs) of hepatitis C virus genotype 1 (HCV-1) patients, sustained virological response at 12 weeks after end of treatment (SVR12) rates greater than 90% have been achieved with 12 weeks of SMV and SOF.

3.  However, less is known about the effectiveness of this regimen in a real-life setting.

What are the new findings?
==========================

1.  In the current meta-analysis based on a total of 15 studies with 1389 HCV-1 patients treated with 12 weeks of SMV+SOF±ribavirin, we demonstrate a pooled SVR12 rate of 86%.

2.  Observational studies had a lower SVR12 rate at 84% compared with RCTs at 94%.

3.  In subgroup analysis, we demonstrated a trend favouring SVR12 in patients with mild fibrosis.

Introduction {#s1}
============

Hepatitis C virus (HCV) is a major global public health issue that affects approximately 185 million people worldwide.[@R1] Chronic infection can lead to significant morbidity (cirrhosis, end-stage liver disease and hepatocellular carcinoma) and mortality.[@R2] Historically, the HCV genotype 1 (HCV-1) has been one of the most difficult genotypes to treat, with sustained virological response (SVR) rates ranging from 24% to 45% on previous standard of care therapy with pegylated-interferon and ribavirin (PEG-IFN+RBV).[@R3] [@R4] The recent development of direct-acting agents (DAAs) has led to dramatically improved treatment outcomes and better tolerated options.[@R2]

Protease-inhibitor-based therapies were part of this new age of highly potent oral agents and carried much promise for patients with HCV.[@R5] While SVR12 rates of up to 80% brought a great deal of enthusiasm to the field,[@R5] universal adoption of this treatment regimen was tempered by significant rates of treatment-limiting adverse events,[@R6] [@R7] and the expectation of newer and safer drugs being developed in the near future.[@R8]

In late 2013, the Food and Drug Administration (FDA) approved second generation DAAs---simeprevir (SMV) and sofosbuvir (SOF)---for use with PEG-IFN and/or RBV.[@R9] Then, in the phase II Combination Of SiMeprevir and sOfosbuvir in HCV genotype 1 infected patientS (COSMOS) trial, the all-oral, IFN-free combination of SMV and SOF with or without RBV (SMV+SOF±RBV) demonstrated SVR12 rates greater than 90% with few adverse events.[@R10] These findings prompted major changes in clinical guidelines by the American Association for the Study of Liver Diseases (AASLD)/Infectious Disease Society of America (IDSA) and European Association for the Study of the Liver (EASL), recommending the use of SMV+SOF±RBV in HCV-1 patients with IFN ineligibility/intolerance or prior treatment failure.[@R11] [@R12] Shortly after these recommendations were made, the FDA approved SMV+SOF±RBV for HCV-1 as a 12-week regimen in patients without cirrhosis and a 24-week regimen in patients with cirrhosis.[@R9]

Evidence supporting the recommendations made by professional societies and FDA approval were mostly based on limited data from randomised controlled trials (RCTs) with small sample sizes and heterogeneous study designs. Currently, less is known regarding treatment outcomes in real-world cohorts. Therefore, we sought to perform a meta-analysis of available data to evaluate the effectiveness of SMV+SOF±RBV for 12 weeks in HCV-1 patients from real-world settings compared with RCTs.

Methods {#s2}
=======

Literature search {#s2a}
-----------------

In June 2015, we performed a literature search to evaluate studies of SMV and SOF combination therapy. We identified articles through a search of MEDLINE and EMBASE databases using the term: 'simeprevir'. We used the same search term to manually identify relevant abstracts from major scientific conferences held in 2014 by the AASLD, Digestive Disease Week (DDW), Asian Pacific Association for the Study of the Liver (APASL), EASL and World Transplant Congress, and, in 2015, by EASL. No restrictions on language, date or geography were applied.

Study selection {#s2b}
---------------

After duplicate studies were removed, the remaining records were evaluated based on titles and abstracts. Criteria for inclusion were original studies with SVR12 data on ≥5 patients treated with 12 weeks of SMV+SOF±RBV. Studies were excluded if patients were co-infected with HIV, hepatitis B and/or hepatitis D, or if they were liver transplant recipients. Two authors (BEY and NHN) independently screened articles for inclusion. Discrepancies were evaluated by a third author (MHN) and resolved by consensus.

Data abstraction {#s2c}
----------------

A data abstraction form was designed for this study to collect the following data: study design, study type, practice setting, collaboration (single vs multicentre) and patient demographics including age, gender, ethnicity, viral load, degree of fibrosis/cirrhosis and (sub) genotype. We also obtained data on treatment outcomes including end of treatment response, SVR at 4 weeks after end of treatment and SVR12, as well as safety and tolerability data on side effects, dose reductions, interruptions and/or withdrawals from treatment.

Statistical analysis {#s2d}
--------------------

The primary outcome of this study was the pooled rate of SVR12. Secondary outcomes included subgroup analysis of characteristics between studies (ie, study design and study type) and characteristics within studies (ie, severity of fibrosis and subgenotype). We calculated pooled event rates for each outcome, using a random-effects model with corresponding 95% CIs.[@R13] We assessed for heterogeneity using the Cochrane Q-statistic with p≤0.10 and I^2^ statistic ≥50%.[@R13] We produced ORs with corresponding 95% CIs for subgroup analyses. Additionally, we utilised funnel plots of ln (OR) against SE with Egger\'s test to assess for publication bias and one-study removed method to evaluate for the disproportionate influence of any included studies. All statistical analyses were conducted using Comprehensive Meta-analysis Software, V.2 (Biostat, Englewood, New Jersey, USA).

Results {#s3}
=======

Results of literature search {#s3a}
----------------------------

From our literature search, we identified 1139 studies (1014 articles from MEDLINE/EMBASE and 125 abstracts from major liver meetings held in 2014 and 2015). After removing duplicates, 882 records were screened for eligibility. A total of 47 studies were assessed in their entirety. Of those, 32 were excluded for reasons described in [figure 1](#BMJGAST2015000056F1){ref-type="fig"}. Ultimately, 15 studies (4 full-length articles and 11 abstracts) met all eligibility criteria.

![PRISMA flow diagram of study selection. SVR12, sustained virological response at 12 weeks after end of treatment.](bmjgast2015000056f01){#BMJGAST2015000056F1}

Characteristics of included studies {#s3b}
-----------------------------------

Fifteen studies with a total of 1389 HCV-1 patients treated with 12 weeks of SMV+SOF±RBV were included in this meta-analysis.[@R10] [@R14] Study characteristics are summarised in [table 1](#BMJGAST2015000056TB1){ref-type="table"}. All were conducted in the USA. Two were RCTs.[@R10] [@R24] Thirteen were observational studies: seven were prospective[@R16] [@R22] [@R23] and six were retrospective.[@R14] [@R15] [@R21] [@R25] Mean age ranged from 58 to 63 years. Most patients were male (53--81%).

###### 

Characteristics of included studies

  -------------------------------------------------------------------------------------------------------------------------------------------------
  First author, year published    Study design    Collaboration   Patients with SVR12 data   Mean age (years)   Male\          Advanced fibrosis\
                                                                                                                N (%)          N (%)
  ------------------------------- --------------- --------------- -------------------------- ------------------ -------------- --------------------
  Aqel, 2015[@R14]                Retrospective   Multicentre     119                        60                 73 (61)        119 (100)

  Bichoupan, 2015[@R15]           Retrospective   Single centre   97                         60\*               Not reported   278 (54)

  Capraru, 2014[@R16]             Prospective     Single centre   34                         57.7               31 (66)        Not reported

  Czul, 2015[@R17]                Prospective     Single centre   9                          Not reported       Not reported   16 (89)

  Dieterich, 2014[@R18]           Prospective     Multicentre     276                        59                 181 (57)       145 (45)

  Kwo, 2015[@R19]                 Prospective     Multicentre     155                        56\*               82 (53)        0 (0)

  Lawitz, 2014[@R10]              RCT             Multicentre     82                         Not reported       58 (81)        41 (50)

  Lawitz, 2015[@R20]              Prospective     Multicentre     103                        58\*               83 (81)        103 (100)

  Lin, 2014[@R21]                 Retrospective   Multicentre     121                        57.7               103 (70)       84 (57)

  Lingala S *et al*, 2014[@R22]   Prospective     Single centre   19                         59                 16 (64)        Not reported

  Modi, 2014[@R23]                Prospective     Multicentre     32                         59\*               34 (76)        Not reported

  Pearlman, 2015[@R24]            RCT             Single centre   58                         58                 38 (66)        58 (100)

  Roytman, 2015[@R25]             Retrospective   Single centre   52                         61.5               63 (64)        62 (63)

  Saxena, 2015[@R26]              Retrospective   Multicentre     156                        62\*               95 (61)        156 (100)

  Singh, 2015[@R27]               Retrospective   Single centre   76                         62.8               Not reported   78 (100)
  -------------------------------------------------------------------------------------------------------------------------------------------------

\*Median age presented.

RCT, randomised controlled trial; SVR12, sustained virological response at 12 weeks after end of treatment.

SVR12 {#s3c}
-----

The overall rate of SVR12 was 85.6% (CI 81.3% to 89.0%) based on 1389 HCV-1 patients pooled from 15 studies. Significant heterogeneity (Q-statistic=48.035, p=0.000, I^2^=70.85%; [figure 2](#BMJGAST2015000056F2){ref-type="fig"}) and publication bias (Egger\'s two-tailed p=0.033) were observed among the eligible studies. On one-study removed influence analysis, the pooled rate of SVR12 varied by no more than approximately 2%. On subgroup analysis by study design, we found an SVR12 rate of 93.5% (CI 85.7% to 97.2%) based on 2 RCTs, compared with 83.9% (CI 79.4% to 87.5%) based on 13 observational studies ([figure 3](#BMJGAST2015000056F3){ref-type="fig"}).

![Pooled rate of sustained virological response at 12 weeks after end of treatment in all hepatitis C virus genotype 1 patients treated with simeprevir and sofosbuvir±ribavirin.](bmjgast2015000056f02){#BMJGAST2015000056F2}

![Sustained virological response at 12 weeks after end of treatment subgroup analysis by study design: observational versus randomised controlled trial (RCT).](bmjgast2015000056f03){#BMJGAST2015000056F3}

Mild compared with advanced fibrosis {#s3d}
------------------------------------

Five studies[@R10] [@R18] [@R19] [@R21] [@R25] provided SVR12 data on a total of 343 patients with mild fibrosis. The pooled rate of SVR12 was 93.0% (CI 86.2% to 96.6%). Significant heterogeneity was observed among these studies (Q-statistic=9.867, p=0.043, I^2^=59.46%).

Nine studies[@R10] [@R14] [@R18] [@R20] [@R21] [@R24] provided SVR12 data on a total of 711 patients with advanced fibrosis. These studies used different definitions to classify patients with advanced fibrosis; seven defined advanced fibrosis as presence of cirrhosis[@R14] [@R18] [@R20] [@R21] [@R25] while two used the METAVIR scoring system.[@R10] [@R24] The pooled rate of SVR12 was 81.5% (CI 75.7% to 86.1%) for patients with advanced fibrosis. Significant heterogeneity was observed among these studies (Q-statistic=22.68, p=0.004, I^2^=64.72%).

In direct comparison of four studies with a total of 387 patients (188 with mild fibrosis; 199 with advanced fibrosis), a trend favouring SVR12 in patients with mild fibrosis over advanced fibrosis was found, OR 2.22 (CI 0.78 to 6.25, p=0.131; [figure 4](#BMJGAST2015000056F4){ref-type="fig"}). There was significant heterogeneity among these studies (Q-statistic=6.29, p=0.098, I^2^=52.31%).

![Odds of sustained virological response at 12 weeks after end of treatment (SVR12) by severity of fibrosis: mild versus advanced fibrosis.](bmjgast2015000056f04){#BMJGAST2015000056F4}

Subtypes of hepatitis C genotype 1 {#s3e}
----------------------------------

On subgroup analysis of hepatitis C genotype 1a compared with genotype 1b, the pooled rates of SVR12 were 89.9% (CI 81.9% to 94.6%) in HCV-1a and 89.0% (CI 78.9% to 94.6%) in HCV-1b. No significant association between hepatitis C genotype 1 subtype and SVR12 was observed, OR 1.35 (CI 0.75 to 2.42, p=0.322; [figure 5](#BMJGAST2015000056F5){ref-type="fig"}).

![Odds of sustained virological response at 12 weeks after end of treatment (SVR12) by subtype: hepatitis C virus genotype 1a (HCV-1a) versus genotype 1b (HCV-1b).](bmjgast2015000056f05){#BMJGAST2015000056F5}

Tolerability {#s3f}
------------

Based on available tolerability data, the most common pooled side effects were: headache 15.2% (n=55/361), fatigue 12.1% (n=78/646), nausea 9.49% (n=50/527) and rash 9.3% (n=68/728). Insufficient data were available to evaluate for withdrawal from treatment and serious adverse events.

Discussion {#s4}
==========

Currently, there are few published studies with treatment data on SMV+SOF±RBV.[@R10] [@R14] [@R24] [@R26] While findings from the COSMOS study were highly promising, study patients were recruited, and stratified into different treatment durations and severity of fibrosis, and only 82 patients received SMV+SOF±RBV for 12 weeks.[@R10] In a separate RCT by Pearlman *et al*,[@R24] the authors recruited 58 patients to the treatment arm with 12 weeks of SMV+SOF±RBV and only included patients with chronic HCV genotype 1a infection and child\'s grade A cirrhosis. Two additional studies on patients with cirrhosis were recently published, but have been limited to retrospective cohorts.[@R14] [@R26] Therefore, given the small sample sizes and heterogeneous study designs of the aforementioned studies, we performed a meta-analysis of available data to provide a more robust estimate of SVR12 in a 12-week regimen of SMV+SOF±RBV.

In our analysis, the overall pooled SVR12 rate was 86%, which was lower than rates reported by the COSMOS trial[@R10] and RCT by Pearlman *et al*.[@R24] This estimate was robust, varying by no more than 2.1% on one-study removed influence analysis. In subgroup analysis comparing observational studies and RCTs, the pooled SVR12 rate was 89%, which reflects a difference in weights due to the dispersion of studies within each subgroup. When evaluating treatment outcomes based on study design, observational studies had a lower SVR12 rate at 84% compared with RCTs at 94%. While this finding is limited since this was not a head-to-head comparison, it may reflect the lower treatment rates of real-world settings.

Our meta-analysis was inclusive of patients with genotypes 1a and 1b as well as varying degrees of fibrosis. Given the more diverse nature of the study population and the uncontrolled environment in which all of the observational studies were conducted, it is not surprising to see that the pooled SVR12 rate is slightly lower than those from RCTs.[@R10] [@R24] However, our treatment rate is still better compared with historical cohorts treated with protease-inhibitor-based therapies,[@R5] which suggests that SMV+SOF±RBV is a more effective treatment option.

In our subgroup analysis of patients with SVR12 and fibrosis data, we observed a higher SVR12 rate in patients with mild fibrosis (93%) compared with those with advanced fibrosis (82%), with a trend favouring SVR12 in patients with mild fibrosis, OR 2.22 (95% CI 0.79 to 6.25, p=0.131). Of the nine studies with SVR12 data on patients with advanced fibrosis, both RCTs[@R10] [@R24] had SVR12 rates greater than 90% while the seven observational studies[@R14] [@R18] [@R20] [@R21] [@R25] had lower SVR12 rates ranging from 68.4% to 88.9%. This finding is likely due to the diversity of real-world patients with more variability in terms of medication adherence, follow-up and comorbidities, compared with the highly selective patients included in clinical trials.

This meta-analysis exclusively evaluated outcomes in HCV-1, the most prevalent genotype in the USA.[@R28] While HCV-1a has been considered the more difficult-to-treat subtype due to NS3 polymorphisms associated with decreased SMV activity[@R1] and a higher likelihood of developing resistance against protease inhibitors,[@R24] [@R29] clinical trials including COSMOS,[@R10] ION-1[@R30] and ION-2[@R31] have shown minimal differences in SVR rates between HCV-1a and HCV-1b. Similarly, our subgroup analysis showed no significant association between HCV-1 subtype and the likelihood of achieving SVR, OR 1.35 (95% CI 0.75 to 2.42, p=0.322), suggesting that a nucleotide polymerase inhibitor such as SOF may serve as an added barrier against the development of resistant variants,[@R1] [@R24] abrogating subclinical differences between subtypes.

Limitations to our study include insufficient data to evaluate serious adverse events, perform subgroup analysis of treatment with or without RBV, and compare outcomes in treatment naïve and experienced patients. An additional limitation was publication bias in our pooled estimate of SVR12, where smaller studies with larger than average effect sizes were more likely to be published, and this finding was statistically significant. In conducting our literature search, we attempted to be as comprehensive as possible, including preliminary data from abstracts presented at major scientific conferences in addition to four full-length articles. We also attempted to give a more conservative estimate of the pooled effect by using a random-effects model. More information on SMV+SOF±RBV will become available in the future, with clinical trials underway to address the efficacy and tolerability of SMV+SOF±RBV in special populations including those with cirrhosis,[@R32] HIV co-infection,[@R33] liver transplantation[@R34] and HCV genotype 4.[@R35] In the meantime, and despite the limitations described above, our study is currently the largest to evaluate the effectiveness of SMV+SOF±RBV for 12 weeks in HCV-1 patients in real-world settings, which included several university centres and the TRIO network data gathered from patients managed by practitioners from the community (n=152) as well as from academic centres (n=82).

In summary, our results support SMV+SOF±RBV as a treatment option for HCV-1 patients. While this rate is slightly lower than that seen in the COSMOS trial alone, our findings are likely more representative of the diverse patient population encountered in routine clinical settings. Given the rapid evolution in HCV therapy and need to optimise treatment, our meta-analysis provides a robust estimate of SVR12 in HCV-1 patients treated with SMV+SOF±RBV.
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